HEIDELBERG, Germany, February 12 /PRNewswire/ -- SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports its financial results for the period ended 31 December 2007.

Q3-Financials

- Cash including marketable securities amounted to EUR21.3 million, a reduction of EUR5.4 million since the beginning of the financial year. Long term liabilities amounted to EUR8 million resulting from a loan which is not due before 2015

- Net loss of EUR1.9 million down from EUR2.5 million for the same period in the previous year

- Revenues increased to EUR0.2 million up from EUR0.0 million for the same period in the previous year

- Operating expenses were EUR2.1 million down from EUR2.7 million for the same period in the previous year

Highlights

- Entering into a long-term collaboration with Dr. Reddy's Laboratories for the production and supply of AX200 for both clinical development and eventual commercialisation, in a broad range of CNS indications, including Stroke, Amyotrophic Lateral Sclerosis and Spinal Cord Injuries.

- Implementation of a stock option plan after approval by SYGNIS' Annual General Meeting of November 2007.

Management Board expects business development to continue according to plan in the fourth quarter of fiscal year 2007/2008.

Outlook

The Company confirms its plans to increase investments in its clinical and pre-clinical development programmes, as well as into the acquisition of external programmes within the next 12 months. The Company anticipates that its strong cash position will enable all existing clinical and pre-clinical projects to be financed over the next three years and the Company is therefore well positioned for sustainable business development. In addition to the existing liquidity, SYGNIS has access to an additional EUR18.3 million resulting from a contractual commitment from its main investors. The Company is, alongside, keeping under review the possibility of a capital raise to accelerate its growth.

For the current financial year SYGNIS anticipates the annual net loss as well as the cash outflow to amount to approx. EUR8 million.

Financial figures 3rd Quarter of financial year 2007/08 as of December 31, 2007 and corresponding figures (IFRS) Numbers in million euros Q3 2007/08 Q3 2006/07 Revenue 0.2 0.0 Total costs 2.1 2.7 EBIT -2.0 -2.6 Result of the period -1.9 -2.5 Intangible assets 17.9 14.9 Liquidity at end of quarter 21.3 28.8 Equity 31.4 35.2 (equity ratio in %) (72) (75) Long-term financial liabilities 8.0 8.0 Operational Cash Flow -1.5 -2.1

Financial Figures for the first nine months of financial year 2007/08 as of December 31, 2007 and corresponding figures (IFRS) Numbers in million euros 9M 2007/08 9M 2006/07 Revenue 0.4 0.1 Total costs 5.9 3.7 EBIT -5.6 -3.6 Result of the period -4.8 -2.9 Operational Cash Flow -4.0 -2.6

For the interim report regarding the first nine months of fiscal year 2007/2008, please visit http://www.sygnis.de.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialty pharmaceutical Company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include Stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease and neurological disorders resulting from injuries of the brain or spinal cord. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available.

One of the central elements in this value-creation chain is the continued development of the existing product pipeline. This is achieved by testing the Company's proprietary compounds, which are already under development, in a number of further CNS indications and forms of administration ("line extension"). By means of specific R&D programs at SYGNIS, new pre-clinical drug candidates are identified and evaluated and suitable CNS product candidates are also systematically tested for the purpose of acquisition or in-licensing.

Disclaimer

Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

For further information, please contact: Dr. Franz-Werner Haas Vice President Operations +49(0)6221-454-812 franz-werner.haas@sygnis.de Media-Contact: Julia Phillips Financial Dynamics Tel.: +44(0)20-7269-7187

For further information, please contact: Dr. Franz-Werner Haas, Vice President Operations, +49(0)6221-454-812, franz-werner.haas@sygnis.de; Media-Contact: Julia Phillips, Financial Dynamics, Tel.: +44(0)20-7269-7187